Welcome to our dedicated page for Arteris SEC filings (Ticker: AIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Arteris, Inc. (Nasdaq: AIP) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Arteris describes itself as a global leader in system IP used in semiconductors, and its filings offer formal detail on the financial and operational aspects behind that business.
Among the key documents are current reports on Form 8-K, which Arteris uses to furnish press releases announcing quarterly financial results and other material events. For example, the company has filed 8-Ks referencing press releases on results for quarters ended June 30 and September 30, including metrics such as revenue, licensing and royalty performance, operating loss, and Remaining Performance Obligations. These filings give investors structured insight into how Arteris’ licensing, support and maintenance, and variable royalty revenue streams are evolving.
Users can also review other periodic reports, such as Forms 10-Q and 10-K when available, to understand topics like segment performance, risk factors, and detailed financial statements that complement the high-level figures cited in press releases. For those interested in governance and ownership, SEC filings are the place where proxy statements and beneficial ownership reports would appear.
Stock Titan enhances this information by pairing real-time updates from EDGAR with AI-powered summaries that highlight the main points of lengthy filings. Instead of reading every line of a multi-page 10-K or 10-Q, users can rely on AI explanations to quickly identify revenue trends, key risks, and notable changes. The platform also surfaces insider transaction reports on Form 4 when filed, helping investors monitor trading activity by Arteris officers and directors.
By using this page, investors and researchers can efficiently navigate Arteris’ official SEC disclosures, from earnings-related 8-Ks to comprehensive annual and quarterly reports, supported by AI tools that make complex documents easier to interpret.
Arteris, Inc. director, President and CEO K. Charles Janac reported an indirect open-market sale of 70,000 shares of Common Stock at a weighted average price of $19.0398 per share. The shares were sold on April 8, 2026 by Bayview Legacy, LLC, an entity for which Janac serves as manager and has voting and dispositive power.
The sale was executed under a Rule 10b5-1 trading plan adopted on March 5, 2025. After the transactions reported, indirect holdings through Bayview Legacy, LLC were 9,119,071 shares, direct holdings were 196,729 shares, and 56,252 shares were held indirectly via the Charles and Lydia Janac Trust, for which Janac serves as trustee.
Bayview Legacy, LLC, a ten percent owner of Arteris, Inc., reported an open-market sale of 70,000 shares of Arteris common stock. The sale occurred on April 8, 2026 at a weighted average price of $19.0398 per share, with individual trade prices ranging from $18.67 to $19.43.
The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 5, 2025 by K. Charles Janac, the manager of Bayview Legacy, LLC. Following the sale, Bayview Legacy, LLC indirectly held 9,119,071 shares of Arteris common stock, over which Janac is deemed to have voting and dispositive power.
AIP filed a Form 144 notifying the proposed sale of 70,000 shares of Common Stock. The cover line lists an aggregate value of $1,268,400.00 and shows Nasdaq as the market with an as of date of 04/08/2026. The filing also lists prior private acquisitions of 50,000 and 20,000 shares (11/05/2013 and 02/05/2016 respectively) and discloses recent 10b5-1 sales by related holders, including sales of 11,800 shares on 04/06/2026 for K. Charles Janac and 32,988 shares on 03/26/2026 for Bayview Legacy, LLC.
Kunkel Joachim reported acquisition or exercise transactions in this Form 4 filing.
Arteris, Inc. director Joachim Kunkel received 899 shares of common stock as a fully vested restricted stock award. The award represents retainer fees he chose to take in shares instead of cash.
The grant was based on the average Arteris trading price of $15.98 over the period from February 20, 2026 through April 2, 2026. Following this award, he holds 69,627 shares of Arteris common stock directly. Kunkel elected to defer the receipt of these shares.
Arteris, Inc. director Claudia F. Munce received a grant of 860 shares of fully vested restricted common stock as part of her board retainer. The shares represent fees she chose to take in stock instead of cash, based on an average trading price of $15.98 for Arteris common stock between February 20, 2026 and April 2, 2026. After this compensation-related acquisition, she holds 101,711 shares directly. The filing notes she elected to defer the receipt of these shares.
Arteris, Inc. VP and Chief Financial Officer Nicholas B. Hawkins reported four open-market sales of common stock on April 2, 2026, totaling 4,870 shares at $17.6528 per share. According to the disclosure, these sales were executed under a mandatory “sell to cover” arrangement to fund tax withholding obligations arising from the release of restricted stock units, rather than discretionary trades. Following the final sale, Hawkins directly held 118,614 shares of Arteris common stock.
Arteris, Inc. Chief Operating Officer Laurent R. Moll reported multiple open-market sales of common stock primarily to cover taxes from the release of restricted stock units. He sold a total of 7,154 shares at prices between $17.65 and $18.23 per share and now directly holds 280,972 shares. According to the disclosure, these sales were required under the company’s equity plans as “sell to cover” transactions and were executed pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2025, indicating they were not discretionary trades.
Arteris, Inc. President and CEO Charles Janac reported tax-related stock sales. He sold a total of 20,809 shares of common stock in open-market transactions on April 2 and April 6, 2026 at weighted average prices of about $17.6528 and $18.3394 per share.
The company explains these sales were made solely to satisfy his tax liability from the release of restricted stock units under a mandated “sell to cover” feature of its equity incentive plans, and are not discretionary trades. The filing also notes the transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on March 5, 2025.
After these trades, Janac holds 196,729 shares directly, plus indirect holdings of 9,189,071 shares through Bayview Legacy, LLC and 56,252 shares through the Charles and Lydia Janac Trust, where he has voting and dispositive authority.
Arteris, Inc. VP and General Counsel Paul L. Alpern reported mandated sales of common stock to cover taxes from restricted stock unit vesting. On April 2, 2026, he sold a total of 3,649 shares at $17.6528 per share in open-market transactions.
The footnote explains these were "sell to cover" trades required under Arteris’ equity incentive plans to satisfy tax withholding obligations, and were not discretionary. After these sales, Alpern continues to hold 86,386 shares of Arteris common stock directly.
BAYVIEW LEGACY, LLC reported multiple 10b5-1 sales of Common stock. The transactions occurred between 01/08/2026 and 03/26/2026, with individual trades including 50,000 shares on 01/08/2026 for $829,155.00 and 41,000 shares on 03/09/2026 for $582,626.40. The filing also lists 11,800 Restricted Stock Units dated 04/01/2026.